Your browser doesn't support javascript.
loading
Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy.
Ogata, Hiroaki; Koga, Chinami; Yanagihara, Toyoshi; Moriuchi, Yuki; Enokizu-Ogawa, Aimi; Ishimatsu, Akiko; Otsuka, Junji; Taguchi, Kazuhito; Moriwaki, Atsushi; Tokunaga, Eriko; Yoshida, Makoto.
Affiliation
  • Ogata H; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Koga C; Department of Breast Oncology NHO Kyushu Cancer Center Fukuoka Japan.
  • Yanagihara T; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Moriuchi Y; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Enokizu-Ogawa A; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Ishimatsu A; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Otsuka J; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Taguchi K; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Moriwaki A; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
  • Tokunaga E; Department of Breast Oncology NHO Kyushu Cancer Center Fukuoka Japan.
  • Yoshida M; Department of Respiratory Medicine NHO Fukuoka National Hospital Fukuoka Japan.
Respirol Case Rep ; 12(3): e01320, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38455504
ABSTRACT
This report presents the case of a 42-year-old Japanese woman with recurrent hormone receptor-positive breast cancer who developed eosinophilic pneumonia (EP) during treatment with abemaciclib combined with endocrine therapy. Seven years after a radical surgery and definite diagnosis of Stage I breast cancer, her cancer recurred with metastases to multiple organs. Initially treated with abemaciclib plus letrozole and goserelin for 3 months, she developed EP, which improved after the discontinuation of anti-cancer treatment and the administration of prednisolone. However, EP occurred again upon the reintroduction of endocrine therapy (i.e., letrozole and goserelin). It improved gradually with the suspension of endocrine therapy and the re-administration of prednisolone. This case underscores the need for further research into the prevention and management of EP in patients receiving abemaciclib with endocrine therapy for advanced breast cancer.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Respirol Case Rep Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Respirol Case Rep Year: 2024 Document type: Article